In vitro and in vivo performance of dry powder inhalation formulations: Comparison of particles prepared by thin film freezing and micronization

AAPS PharmSciTech

Volumn 15, Issue 4, 2014, Pages 981-993

  Wang, Yi Bo ^a   Watts, Alan B ^a   Peters, Jay I ^b   Liu, Sha ^a   Batra, Ayesha ^a   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

dry powder inhalation; lung bioavailability; lung clearance; micronized; thin film freezing

Indexed keywords

TACROLIMUS; EXCIPIENT; IMMUNOSUPPRESSIVE AGENT; POWDER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; DRY POWDER; DRY POWDER INHALER; ENTHALPY; FEMALE; FILM; FREEZE DRYING; FREEZING; GLASS TRANSITION TEMPERATURE; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; INHALATION; LASER DIFFRACTION; LUNG ALVEOLUS MACROPHAGE; LUNG CLEARANCE; LUNG MINUTE VOLUME; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MICRONIZATION; MOLECULAR INTERACTION; MOLECULE; MUCOCILIARY CLEARANCE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STATIC ELECTRICITY; SYSTEMIC CIRCULATION; TEMPERATURE STRESS; X RAY DIFFRACTION; ADMINISTRATION AND DOSAGE; ANIMAL; BIOAVAILABILITY; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; LUNG; MEDICINAL CHEMISTRY; METABOLISM; PHARMACEUTICS; PHARMACOKINETICS; POROSITY; POWDER; PROCEDURES; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INHALATION; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EXCIPIENTS; FEMALE; FREEZING; IMMUNOSUPPRESSIVE AGENTS; LUNG; MALE; PARTICLE SIZE; POROSITY; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84905107629     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0126-7     Document Type: Article

References (61)

1. Yusen RD, Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, et al. The registry of the international society for heart and lung transplantation: thirtieth adult lung and heart-lung transplant report-2013; focus theme: age. J Heart Lung Transplant. 2013;32(10):965-78.
2. Boehler A, Estenne M. Obliterative bronchiolitis after lung transplantation. Curr Opin Pulm Med. 2000;6:133-9.
3. Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J. 2004;23(1):159-71. (Pubitemid 38088513)
4. Watts AB, Peters JI, Talbert RL, O'Donnell KP, Coalson JJ, Williams 3rd RO. Preclinical evaluation of tacrolimus colloidal dispersion for inhalation. Eur J Pharm Biopharm. 2011;77(2):207-15.
5. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987;40(9):1256-65. (Pubitemid 17138110)
6. Hariharan S, Peddi VR, Munda R, Demmy AM, Schroeder TJ, Alexander JW, et al. Long-term renal and pancreas function with tacrolimus rescue therapy following kidney/pancreas transplantation. Transplant Proc. 1997;29(1-2):652-3. (Pubitemid 27123568)
7. Keenan RJ, Konishi H, Kawai A, Paradis IL, Nunley DR, Iacono AT, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg. 1995;60(3):580-4. discussion 4-5.
8. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A, Uk, et al. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002;360(9340):1119-25.
9. Knoop C, Thiry P, Saint-Marcoux F, Rousseau A, Marquet P, Estenne M. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. Am J Transplant. 2005;5(6):1477-82. (Pubitemid 40839441)
10. Wagner K, Webber SA, Kurland G, Boyle GJ, Miller SA, Cipriani L, et al. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. J Heart Lung Transplant. 1997;16(3):275-82. (Pubitemid 27138291)
11. Corcoran TE. Inhaled delivery of aerosolized cyclosporine. Adv Drug Deliv Rev. 2006;58(9-10):1119-27. (Pubitemid 44780909)
12. Groves S, Galazka M, Johnson B, Corcoran T, Verceles A, Britt E, et al. Inhaled cyclosporine and pulmonary function in lung transplant recipients. J Aerosol Med Pulm Drug Deliv. 2010;23(1):31-9.
13. Onoue S, Sato H, Kawabata Y, Mizumoto T, Hashimoto N, Yamada S. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. J Control Release. 2009;138(1):16-23.
14. Onoue S, Sato H, Ogawa K, Kojo Y, Aoki Y, Kawabata Y, et al. Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats. Eur J Pharm Biopharm. 2012;80(1):54-60.
15. Wang T, Noonberg S, Steigerwalt R, Lynch M, Kovelesky RA, Rodriguez CA, et al. Preclinical safety evaluation of inhaled cyclosporine in propylene glycol. J Aerosol Med. 2007;20(4):417-28.
16. Behr J, Zimmermann G, Baumgartner R, Leuchte H, Neurohr C, Brand P, et al. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J Aerosol Med Pulm Drug Deliv. 2009;22(2):121-30.
17. Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006;354(2):141-50. (Pubitemid 43076711)
18. Ide N, Nagayasu T, Matsumoto K, Tagawa T, Tanaka K, Taguchi T, et al. Efficacy and safety of inhaled tacrolimus in rat lung transplantation. J Thorac Cardiovasc Surg. 2007;133(2):548-53. (Pubitemid 46136247)
19. Ingu A, Komatsu K, Ichimiya S, Sato N, Hirayama Y, Morikawa M, et al. Effects of inhaled FK506 on the suppression of acute rejection after lung transplantation: use of a rat orthotopic lung transplantation model. J Heart Lung Transplant. 2005;24(5):538-43. (Pubitemid 40693875)
20. Morishita Y, Hirayama Y, Miyayasu K, Tabata K, Kawamura A, Ohkubo Y, et al. FK506 aerosol locally inhibits antigen-induced airway inflammation in guinea pigs. Int Arch Allergy Immunol. 2005;136(4):372-8. (Pubitemid 41094501)
21. Deuse T, Blankenberg F, Haddad M, Reichenspurner H, Phillips N, Robbins RC, et al. Mechanisms behind local immunosuppression using inhaled tacrolimus in preclinical models of lung transplantation. Am J Respir Cell Mol Biol. 2010;43(4):403-12.
22. Schrepfer S, Deuse T, Reichenspurner H, Hoffmann J, Haddad M, Fink J, et al . Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. Am J Transplant. 2007;7(7):1733-42. (Pubitemid 46905447)
23. Sinswat P, Overhoff KA, McConville JT, Johnston KP, Williams 3rd RO. Nebulization of nanoparticulate amorphous or crystalline tacrolimus-single-dose pharmacokinetics study in mice. Eur J Pharm Biopharm. 2008;69(3):1057-66.
24. Watts AB, Cline AM, Saad AR, Johnson SB, Peters JI, Williams 3rd RO. Characterization and pharmacokinetic analysis of tacrolimus dispersion for nebulization in a lung transplanted rodent model. Int J Pharm. 2010;384(1-2):46-52.
25. Chougule M, Padhi B, Misra A. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. Int J Nanomedicine. 2007;2(4):675-88.
26. Watts AB, Wang YB, Johnston KP, Williams 3rd RO. Respirable low-density microparticles formed in situ from aerosolized brittle matrices. Pharm Res. 2013;30(3):813-25.
27. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, et al. Large porous particles for pulmonary drug delivery. Science. 1997;276(5320):1868-71. (Pubitemid 27443665)
28. Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res. 1999;16(11):1735-42. (Pubitemid 29530407)
29. Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML, et al. Hollow porous particles in metered dose inhalers. Pharm Res. 2000;17(2):168-74. (Pubitemid 30158365)
30. Duddu SP, Sisk SA, Walter YH, Tarara TE, Trimble KR, Clark AR, et al. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere powder. Pharm Res. 2002;19(5):689-95. (Pubitemid 34553679)
31. Richardson PC, Boss AH. Technosphere insulin technology. Diabetes Technol Ther. 2007;9 Suppl 1:S65-72.
32. Plumley C, Gorman EM, El-Gendy N, Bybee CR, Munson EJ, Berkland C. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int J Pharm. 2009;369(1-2):136-43.
33. Geiser M. Update on macrophage clearance of inhaled microand nanoparticles. J Aerosol Med Pulm Drug Deliv. 2010;23(4):207-17.
34. Yang W, Johnston KP, Williams 3rd RO. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur J Pharm Biopharm. 2010;75(1):33-41.
35. Olsson B, Bondesson E, Borgstrom L. Pulmonary drug metabolism, clearance, and absorption. In: Controlled pulmonary drug delivery [Internet]. New York, NY: Springer; 2011. 1. Available from: doi:10.1007/978-1-4419-9745-6.
36. Mobley C, Hochhaus G. Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov Today. 2001;6(7):367-75. (Pubitemid 32208651)
37. Esmailpour N, Hogger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J. 1997;10(7):1496-9. (Pubitemid 27311061)
38. Thorsson L, Edsbacker S, Kallen A, Lofdahl CG. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol. 2001;52(5):529-38.
39. Engstrom JD, Lai ES, Ludher BS, Chen B, Milner TE, Williams 3rd RO, et al. Formation of stable submicron protein particles by thin film freezing. Pharm Res. 2008;25(6):1334-46.
40. Ball DJ, Hirst PH, Newman SP, Sonet B, Streel B, Vanderbist F. Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder device. Int J Pharm. 2002;245(1-2):123-32. (Pubitemid 35299898)
41. Mitchell JP. Practices of coating collection surfaces of cascade impactors: a survey of members of the European Pharmaceutical Aerosol Group (EPAG). Drug Deliv Lung. 2003;14:75-8.
42. Marple VA, Olson BA, Santhanakrishnan K, Mitchell JP, Murray SC, Hudson-Curtis BL. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part II: Archival calibration. J Aerosol Med. 2003;16(3):301-24. (Pubitemid 37169640)
43. Moyano MA, Simionato LD, Pizzorno MT, Segall AI. Validation of a liquid chromatographic method for determination of tacrolimus in pharmaceutical dosage forms. J AOAC Int. 2006;89(6):1547-51. (Pubitemid 46009910)
44. USP 32-NF 27 General Chapter 601: Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers. 218-39.
45. Gombás A, Szabó-Révész P, Kata M, RJ G, Erõs I. Quantitative determination of crystallinity of a-lactose monohydrate by DSC. J Therm Anal Calorim. 2002;68:503-10. (Pubitemid 34614450)
46. Hilden LR, Morris KR. Physics of amorphous solids. J Pharm Sci. 2004;93(1):3-12. (Pubitemid 38087927)
47. Deng Z, Xu S, Li S. Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications. Int J Pharm. 2008;351(1-2):236-43.
48. Kim AI, Akers MJ, Nail SL. The physical state of mannitol after freeze-drying: effects of mannitol concentration, freezing rate, and a noncrystallizing cosolute. J Pharm Sci. 1998;87(8):931-5. (Pubitemid 28381249)
49. Zidan AS, Rahman Z, Sayeed V, Raw A, Yu L, Khan MA. Crystallinity evaluation of tacrolimus solid dispersions by chemometric analysis. Int J Pharm. 2012;423(2):341-50.
50. Zhao M, Barker SA, Belton PS, McGregor C, Craig DQ. Development of fully amorphous dispersions of a low T(g) drug via co-spray drying with hydrophilic polymers. Eur J Pharm Biopharm. 2012;82(3):572-9.
51. Rasenack N, Muller BW. Micron-size drug particles: common and novel micronization techniques. Pharm Dev Technol. 2004;9(1):1-13. (Pubitemid 38258252)
52. Saleem IY, Smyth HD. Micronization of a soft material: air-jet and micro-ball milling. AAPS PharmSciTech. 2010;11(4):1642-9.
53. Rogueda PG, Traini D. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects. Expert Opin Drug Deliv. 2007;4(6):595-606. 54. de Villiers MM. Influence of cohesive properties of micronized drug powders on particle size analysis. J Pharm Biomed Anal. 1995;13(3):191-8.
54. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci. 1986;75(5):433-8. (Pubitemid 16083635)
55. Zhang J, Wu L, Chan HK, Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev. 2011;63(6):441-55.
56. Alexander DJ, Collins CJ, Coombs DW, Gilkison IS, Hardy CJ, Healey G, et al. Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals. Inhal Toxicol. 2008;20(13):1179-89.
57. Kuehl PJ, Anderson TL, Candelaria G, Gershman B, Harlin K, Hesterman JY, et al. Regional particle size dependent deposition of inhaled aerosols in rats and mice. Inhal Toxicol. 2012;24(1):27-35.
58. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol. 1998;85(2):379-85. (Pubitemid 28365799)
59. Lehnert BE, Morrow PE. Association of 59iron oxide with alveolar macrophages during alveolar clearance. Exp Lung Res. 1985;9(1-2):1-16. (Pubitemid 16207628)
60. Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001;41(5):542-51. (Pubitemid 32381872)
61. Shin SB, Cho HY, Kim DD, Choi HG, Lee YB. Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. Eur J Pharm Biopharm. 2010;74(2):164-71.